Psychedelics


Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

April 13th, 2021 - Ryan Allway

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO Adam George as a director with immediate effect.   Bringing nearly two decades of experience in the pharmaceuticals industry, Adam served as Chief Financial Officer (CFO) for five years at GW Pharmaceuticals, the UK-based drug […]

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

April 13th, 2021 - Ryan Allway

TORONTO-April 13, 2021-(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced plans to advance the pre-clinical work for its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation of CYB004, two of the Company’s deuterated tryptamine development candidates. These studies are part of the […]

Psychedelic Wellness-Focused Company Delic Holdings Provides First Quarter 2021 Shareholder Update

April 12th, 2021 - Ryan Allway

VANCOUVER, BC, April 12, 2021 /PRNewswire/ – Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), a psychedelic wellness-focused company, is pleased to provide the following shareholder update on its operations for the first quarter of 2021. The first quarter of 2021 has been transformative and expansive as DELIC has entered into new sectors of this […]

Psychedelics Wellness Company Delic: Proven Management Team with a Star-Studded Board

April 9th, 2021 - Ryan Allway

The psychedelics  sector is quickly evolving into a multi-billion-dollar industry with a growing number of publicly traded companies. As with any new industry, there are many companies backed by little more than financiers looking to make a quick dollar before moving on to the next opportunity, which makes it important for investors to know who’s […]

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

April 8th, 2021 - Ryan Allway

ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada’s Section 56(1) Exemption VANCOUVER, BC, April 8, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE”) a leader in advanced proprietary technology for psychedelic therapy, […]

Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

April 8th, 2021 - Ryan Allway

VANCOUVER, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to formalize discussions with the U.S. Food and Drug Administration (“FDA”) by filing an End-of-Phase 2 meeting request (EOP2) based […]

Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division

April 8th, 2021 - Ryan Allway

The Facility acquisition positions Havn Life to quickly expand its product portfolio and reach additional NHP categories.   VANCOUVER, BC / ACCESSWIRE / April 8, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce, further to […]

Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical

April 7th, 2021 - Ryan Allway

DENVER, April 07, 2021 — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced its four lead novel drug candidates as the Company prepares for its Pre-Investigational New Drug (IND) meetings with […]

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

April 7th, 2021 - Ryan Allway

Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has finalized an agreement to sublicense the technology covered by its recently announced […]

NeonMind Developing Music Playlist For Psychedelic Therapy Sessions

April 6th, 2021 - Ryan Allway

Vancouver, B.C. – April 6, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (OTC:NMDBF) (“NeonMind”), is pleased to announce the commencement of a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions.  Previous research has established that music for a therapeutic psychedelic session can significantly impact the experience. […]

Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.

April 6th, 2021 - Ryan Allway

NEW YORK, April 6, 2021 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the signing of an agreement between Seelos and AptarGroup, Inc. (NYSE: ATR) for the co-exclusive use and supply of Aptar Pharma’s Bidose (BDS) Liquid System device […]

Core One Labs Vocan Expands Product Commercialization Team

April 6th, 2021 - Ryan Allway

VANCOUVER, BC / ACCESSWIRE / April 6, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (“Core One“) is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan“) has expanded its product commercialization team, adding Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs.   Dr. Matthews will oversee research and development, as well […]

Optimi Health Aims to Expand its Shareholder Base

April 6th, 2021 - Ryan Allway

VANCOUVER, BC (GLOBE NEWSWIRE – April 6, 2021) — Optimi Health Corp. (CSE: OPTI) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the addition of their overseas listing. The commencement of equity trading in Optimi securities is on the premier […]

Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test

April 6th, 2021 - Ryan Allway

HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy   Vancouver, British Columbia–(Newsfile Corp. – April 6, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry’s first Psychedelics […]

MindMed Announces the Publication of New Data on Personalized MDMA Dosing

April 5th, 2021 - Ryan Allway

BASEL, Switzerland, April 5, 2021 /CNW/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, in Basel, Switzerland. This study provides the first scientific […]

PsyBio Strengthens its Leadership Team with Appointment of Dr. Michael Spigarelli as Chief Medical Officer

April 5th, 2021 - Ryan Allway

Dr. Spigarelli’s extensive clinical and research development expertise will be integral in leading PsyBio’s development and clinical goals OXFORD, Ohio and COCONUT CREEK, Fla., April 5, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (“PsyBio“), a biotechnology company pioneering the next generation of targeted psychoactive medications, today announced the appointment of Michael Spigarelli, M.D., Ph.D., […]

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

April 1st, 2021 - Ryan Allway

San Diego, California–(Newsfile Corp. – April 1, 2021) –  Tryp Therapeutics Inc. (CSE: TRYP) (“Tryp” or the “Company“), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has appointed Greg McKee as its Chief Executive Officer. Mr. McKee will also continue in his responsibilities […]

NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference

March 31st, 2021 - Ryan Allway

Vancouver, B.C. – March 30, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FFE: 6UF) (“NeonMind”), a psychedelic drug development company, is pleased to announce that Robert Tessarolo, President & Chief Executive Officer, will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference that will be held virtually from May 4-6. He will be speaking on the use […]

Delic’s Acquisition Target, Complex Biotech Discovery Ventures Ltd., Receives First Research Orders Through Online Payment Platform

March 31st, 2021 - Ryan Allway

After recently launching its Advanced Analytical Testing services, CBDV successfully receives orders through their new online payment platform  VANCOUVER, BC, March 31, 2021 /PRNewswire/ –  Delic Holdings Inc. (the “Company”), (“DELIC”) (CSE: DELC) (OTCQB: DELCF), a psychedelic focused wellness company, is pleased to announce that its acquisition target, Complex Biotech Discovery Ventures Ltd. (“CBDV”), a licensed cannabis and […]

Mindset Pharma Expands Scientific Team: Dr. Malik Slassi Appointed Senior VP Innovation and Ian Dean Appointed Director Preclinical Development

March 30th, 2021 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – March 30, 2021) – Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psilocybin and N,N-Dimethyltryptamine (DMT) inspired medicines and related technologies, is pleased to announce that it has expanded its scientific leadership team with the appointment of Dr. Malik […]

BetterLife Added to the Horizons Psychedelic Stock Index ETF

March 29th, 2021 - Ryan Allway

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU ) is pleased to announce that it has been added to the Horizons Psychedelic Stock Index ETF ( PSYK : NEO), the world’s first ETF offering direct exposure to North American publicly listed securities that have significant business activities […]

Psirenity granted approval to conduct Jamaica’s first psilocybin clinical trial to help manage depression

March 29th, 2021 - Ryan Allway

TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has received approval to conduct the first clinical trial protocol with psilocybin in Jamaica. Psirenity is emerging as a global leader in science-backed brain health and wellness. Its focus is on providing holistic treatments that help […]

MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board

March 29th, 2021 - Ryan Allway

Mind Medicine (MindMed) Inc. (“MindMed”) (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has announced the addition of Dr. Robert C. Malenka, an accomplished neuroscientist and psychiatry professor from Stanford University, to Chair the Company’s Scientific Advisory Board. Dr. Malenka is an elected member of the National Academy of Sciences and […]

Core One Labs Appoints Dr. Stephen Peach as Head of Patient Research

March 29th, 2021 - Ryan Allway

Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) is pleased to announce that its wholly owned subsidiary Rejuva Mental Health Clinic (the “Clinic”) has retained Dr. Stephen Peach as Lead Physician. Dr. Peach will be responsible for developing comprehensive patient intake and assessment protocols, with the goal of identifying individuals with a history of mental health disorders […]

Von der Schildkröte zum Hasen: Wie KI die Arzneimittelentwicklung beschleunigen will

March 26th, 2021 - Ryan Allway

Alexander Flemmings zufällige Entdeckung von Penicillin steht in krassem Gegensatz zu den typischen Prozessen und Zeitplänen, die mit der Entdeckung von Arzneimitteln verbunden sind. Im Gegenteil, die meisten Medikamente werden nicht versehentlich entdeckt, sondern über lange Zeiträume von 5 bis 15 Jahren entwickelt, was viele Millionen Dollar kostet. Grundsätzlich kann der Entwicklungsprozess in zwei Phasen […]

Creso Pharma Receives Commitments Totaling A$18m

March 26th, 2021 - Ryan Allway

Creso Pharma Limited(ASX:CPH, FRA:1X8) (‘Creso Pharma’) is pleased to advise that it has secured firm commitments from institutional, professional and sophisticated investors to raise up to A$18million (before costs) through the issue of approximately 94.7 million new fully paid ordinary shares (“shares”) at an issue price of $0.19 per share(“Placement”). The Placement was heavily oversubscribed […]

Horizons ETFs Completes Rebalance of World’s First Psychedelics ETF

March 26th, 2021 - Ryan Allway

Horizons ETFs Management (Canada) Inc. (“Horizons ETFs“) has completed its first quarterly rebalance of the holdings of the Horizons Psychedelic Stock  Index ETF (PSYK: NEO). PSYK is the world’s first ETF offering direct exposure to North American publicly listed securities that have significant business activities in, or significant exposure to, the psychedelics industry. This quarter, […]

From Tortoise to Hare, How AI Aims to Speed up Drug Development

March 25th, 2021 - Liam Harrison

Alexander Flemming’s accidental discovery of penicillin exists in stark contrast to the typical processes and timelines associated with drug discovery. Most drugs, on the contrary, are not accidentally discovered and are developed over long timelines ranging from 5 to 15 years, costing many millions of dollars. Broadly speaking, the development process can be divided into […]

Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin with Jamaican Company Hypha Wellness

March 25th, 2021 - Ryan Allway

Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP)(“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, has entered into a letter of intent (LOI) with nutraceutical company Hypha Wellness Jamaica Psilocybin (HWJP) towards jointly researching and, subject to compliance with all applicable laws and regulations, producing standardized powdered […]

PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine

March 24th, 2021 - Ryan Allway

Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), today announced that its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), a psychedelics biotech company, has entered into a sponsored research agreement with The Queen’s University of Belfast (“QUB”) for the development of a patented hydrogel-forming microneedle (“MN”) patch to deliver ketamine and the PharmaTher’s proprietary ketamine formulation, KETABET™”. This […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading